Home » Italian Start-up CellPly Snares $2.8M Seed Investment

Italian Start-up CellPly Snares $2.8M Seed Investment

Mar 21, 2014
|
staff reporter

NEW YORK (GenomeWeb News) – Start-up CellPly has attracted €2 million ($2.8 million) in seed capital investment to support development of its technology for determining patient response to oncology therapeutics.

Italian Angels for Growth, Zernike Meta Ventures, and Atlas Seed made the investment into Bologna, Italy-based CellPly in order to support the firm's completion of its diagnostics platform, which is being developed to allow clinicians to assess in vitro a patient's cellular response to cancer treatments, such as chemotherapy and monoclonal antibodies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Drive Resistance

Gene drives might run into biological resistance, the Economist reports.

Dalí DNA Collected

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Synthetic-Conservation Biology Disconnect

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

This Week in Science

In Science this week: full CRISPR locus integration complex structure, and more.

What's Popular?

In Cancer

  1. UW Study Examines Prevalence of Non-Founder BRCA1, BRCA2, Other Mutations in Breast Cancer

  2. Circulating Tumor DNA Dynamics May Hold Hints to Immunotherapy Response, Pseudoprogression

    Premium

  3. Boreal Genomics Develops Method to Increase Accuracy, Reduce Cost of Liquid Biopsy

    Premium

  4. FDA and NCI Memorandum Indicates Growing Interest in Proteogenomics as Clinical Approach

    Premium

  5. Tempus, Rush University Medical Center Collaborate to Expand Hospital's Biobank

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.